Search PubMed⌕ Search

Biomedical subjects

R D Mann

Publications and source records attributed to R D Mann.

81 records · Page 5Linked to original sources
PubMed1967

Effect of age, sex, and diurnal variation on the human fibrinolystic system.

Fibrinolytic activity, as shown by the dilute blood clot lysis time, tends to show a diurnal variation, but is relatively unaffected by age and sex. Mean plasma anti-urokinase activity is consistently and significantly greater in females in the post-menstrual week than in age-matched males, but is relatively unaffected by daily variation and age. This sex difference in the activity of plasma, which is inhibitory to fibrinolysis, is of a degree which makes this measurement important in studies of the fibrinolytic system in healthy persons and disease states.

Adult↗
PubMed1966

Antiplasmin activity of electrophoretically separated human serum fractions.

The antiplasmin which migrates electrophoretically with the alpha(2) globulins preponderates in effect over that of the alpha(1) migrating antiplasmin. This preponderance persists at physiological pH value in vitro and the significance of this finding is discussed. No evidence has been obtained of the existence of anti-urokinase activity in antiplasmin-free serum fractions.

Alpha-Globulins↗
PubMed1966

Method of estimating the inhibitory effect of plasma or serum upon urokinase-activated fibrinolysis.

Activator concentration in the range 50 to 100 Ploug units urokinase is directly proportional to the reciprocal of the lysis time both in the presence and absence of the plasma or serum inhibitors. Inhibitory activity can be estimated, therefore, by the difference in lysis time between control clots containing a buffer or euglobulin component and plasma or serum containing clots both activated by a common concentration of urokinase selected from within the critical range. An experimental model for this purpose is described with an examination of the effects of each variable in this system and a reference curve in terms of a known inhibitor. In this study, it has been found that the effects of calcium are influenced by the plasminogen concentration and are biphasic in the presence of the serum inhibitors.

Calcium↗
PubMedDate not supplied

Prospective cohort study of adverse events monitored by hospital pharmacists. Hospital Adverse Event Monitoring Study (HAEMS) Group.

PURPOSE: To examine the feasibility of pharmacist-led intensive hospital monitoring of adverse events (AEs) associated with newly marketed drugs. SUBJECTS/SETTING: 303 patients admitted to Southampton Hospitals who were prescribed selected newly marketed drugs during their inpatient stay in 1998. METHODS: Prospective observational study. Patients were identified from computerized pharmacy records, clinical pharmacist ward rounds, dispensary records or via nursing staff. The pharmacist reviewed medical notes and recorded AEs, suspected adverse drug reactions (ADRs) and reasons for stopping drugs. OUTCOMES: Incidence of AEs, ADRs; proportionate agreement between the physician's and pharmacist's event recording. RESULTS: 303 patients were monitored. Of the patients taking newly marketed drugs 92% were identifiable using pharmacy computer systems and pharmacist ward visits. There were 21 (7%) suspected ADRs detected during this pilot study. The types of adverse events detected were broadly similar to those identified by general practice-based prescription event monitoring. However, biochemical changes featured more frequently than in general practice. Differences between adverse events recorded by pharmacist and physician were systematic and attributed to differences in event coding. CONCLUSION: Pharmacist-led monitoring in a typical NHS hospital setting was effective at detecting ADRs in newly marketed drugs. However, this effort might have been substantially less time-consuming and more effective were electronic patient records (EPRs) available. Pharmacy computer systems are not designed to be patient focused and are therefore unable to identify patients taking newly marketed drugs. It is argued that future EPR and computerised patient-specific prescribing systems should be designed to capture this data in the same way as some US systems are currently able to do.

Computers↗